During the last session, Keros Therapeutics Inc (NASDAQ:KROS)’s traded shares were 1.73 million, with the beta value of the company hitting 1.37. At the end of the trading day, the stock’s price was $12.02, reflecting an intraday gain of 5.53% or $0.63. The 52-week high for the KROS share is $73.00, that puts it down -507.32 from that peak though still a striking 18.72% gain since the share price plummeted to a 52-week low of $9.77. The company’s market capitalization is $486.90M, and the average intraday trading volume over the past 10 days was 3.19 million shares, and the average trade volume was 1.37 million shares over the past three months.
Keros Therapeutics Inc (KROS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.71. KROS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.43.
Keros Therapeutics Inc (NASDAQ:KROS) trade information
Keros Therapeutics Inc (KROS) registered a 5.53% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.53% in intraday trading to $12.02, hitting a weekly high. The stock’s 5-day price performance is 15.36%, and it has moved by -28.96% in 30 days. Based on these gigs, the overall price performance for the year is -78.06%. The short interest in Keros Therapeutics Inc (NASDAQ:KROS) is 4.31 million shares and it means that shorts have 2.32 day(s) to cover.
The consensus price target of analysts on Wall Street is $100, which implies an increase of 87.98% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $96 and $107 respectively. As a result, KROS is trading at a discount of -790.18% off the target high and -698.67% off the low.
Keros Therapeutics Inc (KROS) estimates and forecasts
Statistics show that Keros Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Keros Therapeutics Inc (KROS) shares have gone down -76.35% during the last six months, with a year-to-date growth rate less than the industry average at 8.85% against 16.50. In the rating firms’ projections, revenue will increase 21,125.47% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 37.32M as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 22.23M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 143k and 83k respectively. In this case, analysts expect current quarter sales to grow by 25,996.63% and then jump by 26,687.14% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -111.11%. While earnings are projected to return 0.22% in 2025.
KROS Dividends
Keros Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Keros Therapeutics Inc (NASDAQ:KROS)’s Major holders
Keros Therapeutics Inc insiders own 2.05% of total outstanding shares while institutional holders control 100.48%, with the float percentage being 102.58%. FMR LLC is the largest shareholder of the company, while 246.0 institutions own stock in it. As of 2024-06-30, the company held over 4.72 million shares (or 16.0279% of all shares), a total value of $215.69 million in shares.
The next largest institutional holding, with 2.51 million shares, is of BLACKROCK INC.’s that is approximately 8.5348% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $114.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of Keros Therapeutics Inc (KROS) shares are Vanguard Total Stock Market Index Fund and ACAP Strategic Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 961.35 shares. This amounts to just over 2.37 percent of the company’s overall shares, with a $11.56 million market value. The same data shows that the other fund manager holds slightly less at 933.99, or about 2.31% of the stock, which is worth about $11.23 million.
